CSF1R and pancreatic ductal adenocarcinoma: Zhu (48) demonstrated in vivo that interrupting signaling by the myeloid growth factor receptor CSF1R in a mouse model of pancreatic ductal adenocarcinoma (PDAC) can effectively reprogram macrophage reactions, causing enhanced antigen presentation and antitumor T cell responses.